Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether Vilazodone is effective in the treatment of symptoms of Social Anxiety Disorder among adults.


Clinical Trial Description

The proposed study is a 12 week double-blind, placebo-controlled trial in which daily doses of vilazodone 20 to 40 mg/day or matching placebo will be administered on a 1:1 ratio. The study will include 30 outpatients age 18-75 with SAD, generalized subtype who return for at least one post randomization visit where efficacy evaluations are conducted. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01712321
Study type Interventional
Source The Medical Research Network
Contact
Status Unknown status
Phase N/A
Start date October 2012
Completion date April 2014

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06274112 - Using TMS to Understand Neural Processes of Social Motivation N/A
Completed NCT02554929 - Treatment of Social Anxiety Disorder and Selective Mutism N/A
Completed NCT00684541 - Interpretation Modification Program for Social Phobia N/A
Completed NCT00684320 - Attention Disengagement Training for Social Phobia N/A
Completed NCT03247075 - Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT N/A
Completed NCT02811458 - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders N/A
Withdrawn NCT04622930 - Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD) N/A
Active, not recruiting NCT05018312 - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety N/A
Active, not recruiting NCT05124639 - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders N/A
Completed NCT05858294 - The Safety, Acceptability and Efficacy of Alena N/A
Active, not recruiting NCT05600114 - Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Not yet recruiting NCT02924610 - Brief Intervention to Reduce Fear Phase 4
Active, not recruiting NCT02592564 - Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder N/A
Recruiting NCT02305537 - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment N/A
Terminated NCT03764644 - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders N/A
Completed NCT01320800 - CBT for Social Anxiety Disorder Delivered by School Counselors Phase 2
Completed NCT00485888 - Flushing in Social Anxiety Disorder on Cipralex Phase 2
Completed NCT00872820 - Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder N/A
Completed NCT00485615 - An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia Phase 2